{"id":"NCT01227902","sponsor":"GlaxoSmithKline","briefTitle":"Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures","officialTitle":"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2010-10-25","resultsPosted":"2013-11-11","lastUpdate":"2014-10-17"},"enrollment":203,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Retigabine IR","otherNames":[]}],"arms":[{"label":"Retigabine IR","type":"EXPERIMENTAL"}],"summary":"The purpose of this Phase III study is to evaluate the efficacy, safety and tolerability and health outcomes of retigabine Immediate Release (IR) as adjunctive therapy to each of the following monotherapy Antiepileptic Drug (AED) treatments: carbamazepine/oxcarbazepine, lamotrigine, levetiracetam, or valproic acid in adult subjects with partial-onset seizures (POS) using a flexible dosing regimen.","primaryOutcome":{"measure":"Number of Participants With a >=50% Reduction in Partial-onset Seizure (POS) Frequency From Baseline","timeFrame":"From Baseline through Week 20 (Day 140)/Early Withdrawal","effectByArm":[{"arm":"RTG Flexible Dose Plus C/O","deltaMin":22,"sd":null},{"arm":"RTG Flexible Dose Plus Lamotrigine","deltaMin":16,"sd":null},{"arm":"RTG Flexible Dose Plus Levetiracetam","deltaMin":22,"sd":null},{"arm":"RTG Flexible Dose Plus Valproic Acid","deltaMin":29,"sd":null},{"arm":"Total","deltaMin":89,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG001","p":null},{"comp":"OG002","p":null},{"comp":"OG003","p":null},{"comp":"OG004","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":13},"locations":{"siteCount":66,"countries":["Belgium","Bulgaria","Denmark","France","Germany","Italy","Netherlands","Poland","Russia","Spain","Thailand","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Dizziness","Somnolence","Vertigo","Fatigue","Asthenia"]}}